Evidence map›Paper›PMID 38674696›Full record

ReviewMicroorganisms2024

Targeting Viral Transcription for HIV Cure Strategies.

Jon Izquierdo-Pujol, Maria C Puertas, Javier Martinez-Picado, Sara Morón-López

Open access · goldAbstract readReview
In one paragraph

Review in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jon Izquierdo-PujolIrsiCaixa, 08916 Badalona, Spain.ORCID 0000-0002-5903-9909
Maria C PuertasIrsiCaixa, 08916 Badalona, Spain.
Javier Martinez-PicadoIrsiCaixa, 08916 Badalona, Spain.ORCID 0000-0002-4916-2129
Sara Morón-LópezIrsiCaixa, 08916 Badalona, Spain.ORCID 0000-0003-0800-9205
IrsiCaixa · ESUniversitat de Vic - Universitat Central de Catalunya · ES

Funding

Reversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0M
MultiOMICS to uncover immune and virological mechanisms that drive HIV DNA decay, restore immune homeostasis, and promote HIV specific immunity in PWH receiving cell therapies.P01AI178376 · NIAID · EMORY UNIVERSITY · PI Rafick Pierre Sekaly · 2023 to 2026
$6.1M
Agència de Gestió d'Ajuts Universitaris i de Recerca 2020 BP 00046Agència de Gestió d'Ajuts Universitaris i de Recerca 2023 FI-1 00207EU HORIZON-HLTH-2021-DISEASE-04-07 101057100EU HORIZON-HLTH-2021-DISEASE-04-07 101095606Fundació La Marató de TV3 202130-30-31-32Generalitat Valenciana PROMETEO/2021/036, SpainMinisterio de Ciencia e Innovación CB21/13/00063Ministerio de Ciencia e Innovación PID2019-109870RB-I00National Institute of Allergy and Infectious Diseases 1P01AI178376-01National Institute of Allergy and Infectious Diseases 1 UM1 AI164561-01NIAID NIH HHS UM1 AI164561
6 · The paper itself

Abstract

Combination antiretroviral therapy (ART) suppresses viral replication to undetectable levels, reduces mortality and morbidity, and improves the quality of life of people living with HIV (PWH). However, ART cannot cure HIV infection because it is unable to eliminate latently infected cells. HIV latency may be regulated by different HIV transcription mechanisms, such as blocks to initiation, elongation, and post-transcriptional processes. Several latency-reversing (LRA) and -promoting agents (LPA) have been investigated in clinical trials aiming to eliminate or reduce the HIV reservoir. However, none of these trials has shown a conclusive impact on the HIV reservoir. Here, we review the cellular and viral factors that regulate HIV-1 transcription, the potential pharmacological targets and genetic and epigenetic editing techniques that have been or might be evaluated to disrupt HIV-1 latency, the role of miRNA in post-transcriptional regulation of HIV-1, and the differences between the mechanisms regulating HIV-1 and HIV-2 expression.

Indexed as

HIVHIV latencyHIV nuclear exportHIV transcriptionlatency-promoting agentslatency-reversing agentsviral persistence

Identifiers

PMID38674696
PMCPMC11052381
OpenAlexW4394580912

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.